Akebia Therapeutics, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

0.919$ -1.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Akebia Therapeutics, Inc. (AKBA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 350 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet AKBA
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	235	242	225	220	207	221	310	346	364	377	363	350
Current Assets	110	118	113	112	100	114	204	235	258	253	243	230
Cash	47	43	42	39	34	52	113	137	166	185	163	156
Cash & Short-Term Investments	47	43	42	39	34	52	113	137	166	185	163	156
Receivables	23	39	27	30	32	34	62	73	66	47	63	54
Inventory	18	16	26	24	20	16	20	17	19	16	13	13
Goodwill	59	59	59	59	59	59	59	59	59	59	59	59
Intangible Assets	45	36	27	18	9.0	–	–	–	–	–	–	–
Total Liabilities	274	272	253	254	258	270	286	316	323	344	335	325
Current Liabilities	80	100	66	107	66	81	91	119	133	163	174	161
Short-Term Debt	13	22	5.1	7.2	7.5	9.7	5.5	5.6	4.9	3.5	12	25
Accounts Payable	9.0	15	12	10	13	15	13	12	10	21	8.4	9.4
Long-Term Debt	35	17	30	38	38	39	47	47	48	48	36	25
Shareholders' Equity	-39	-31	-27	-34	-50	-49	25	29	42	33	27	25
Retained Earnings	-1,610	-1,609	-1,627	-1,636	-1,656	-1,678	-1,672	-1,672	-1,671	-1,684	-1,693	-1,702
Shares Outstanding	188	190	205	210	210	219	242	271	274	265	267	270

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings